Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Zimmer Biomet HoldingsXSWX:ZBH +3.45%76 EV-to-EBITDA is 10.97 as of Jul. 25, 2026, which is 39% below its 10-year median of 18.07. GuruFocus rates XSWX:ZBH with a GF Score™ of 76/100 and a GF Value™ of CHF103.81. The stock has 3 warning signs investors should review. Among 510 Medical Devices & Instruments companies, Zimmer Biomet Holdings ranks better than 64.51% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Zimmer Biomet Holdings's enterprise value is CHF20,202 Mil.
Zimmer Biomet Holdings's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was CHF1,842 Mil. Therefore, Zimmer Biomet Holdings's EV-to-EBITDA for today is 10.97.
The historical rank and industry rank for Zimmer Biomet Holdings's EV-to-EBITDA or its related term are showing as below:
XSWX:ZBH'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 10.04 Med: 18.07 Max: 39.98
Current: 10.71
During the past 13 years, the highest EV-to-EBITDA of Zimmer Biomet Holdings was 39.98. The lowest was 10.04. And the median was 18.07.
XSWX:ZBH's EV-to-EBITDA is ranked better than 64.51% of 510
companies
in the Medical Devices & Instruments industry
Industry Median: 13.845
vs XSWX:ZBH: 10.71
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Zimmer Biomet Holdings's PE Ratio (TTM) for today is calculated as:
Zimmer Biomet Holdings's share price for today is CHF75.00.
Zimmer Biomet Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF3.076.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:ZBH vs STE, PEN, GMED: EV-to-EBITDA Comparison
For the Medical Devices subindustry, Zimmer Biomet Holdings's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zimmer Biomet Holdings EV-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Zimmer Biomet Holdings's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Zimmer Biomet Holdings's EV-to-EBITDA falls into.
Zimmer Biomet Holdings's current Enterprise Value is CHF20,202 Mil.
Zimmer Biomet Holdings's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF1,842 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zimmer Biomet Holdings (XSWX:ZBH) has a EV-to-EBITDA of 10.97 as of Jul. 25, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Zimmer Biomet Holdings. This is 39% below median its historical median of 18.07. Over the past decade, Zimmer Biomet Holdings' EV-to-EBITDA has ranged from 10.04 to 39.98. According to the industry distribution chart, Zimmer Biomet Holdings ranks #181 out of 510 companies in the Medical Devices & Instruments industry, placing it in the top 35.5%.
Is Zimmer Biomet Holdings' EV-to-EBITDA too high?
Zimmer Biomet Holdings' current EV-to-EBITDA of 10.97 is 39% below median its 10-year median of 18.07. Over the past 10 years, this metric has ranged from a low of 10.04 to a high of 39.98. The Medical Devices & Instruments industry median EV-to-EBITDA is 13.85. Zimmer Biomet Holdings' value of 10.97 is 20.8% below this industry median. Based on the distribution chart, Zimmer Biomet Holdings ranks #181 out of 510 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Zimmer Biomet Holdings has a GF Score™ of 76/100, reflecting its overall financial health beyond just this single metric.
How does Zimmer Biomet Holdings' EV-to-EBITDA compare to STE and PEN?
According to the Medical Devices & Instruments industry distribution chart, Zimmer Biomet Holdings ranks #181 out of 510 companies for EV-to-EBITDA. This puts Zimmer Biomet Holdings in the upper half of its industry. The industry median EV-to-EBITDA is 13.85. Zimmer Biomet Holdings' value of 10.97 is 20.8% below this benchmark. Historically, Zimmer Biomet Holdings' own EV-to-EBITDA has ranged from 10.04 to 39.98 over the past decade. While the company's 10-year median is 18.07 vs. the industry median of 13.85, Zimmer Biomet Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Devices & Instruments company?
The median EV-to-EBITDA among Medical Devices & Instruments companies is 13.85, based on 510 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zimmer Biomet Holdings's current EV-to-EBITDA of 10.97 is 20.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Zimmer Biomet Holdings. For the Medical Devices & Instruments industry, the median EV-to-EBITDA is 13.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zimmer Biomet Holdings's current EV-to-EBITDA is 10.97, which is 39% below median its own 10-year median of 18.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zimmer Biomet Holdings stock overvalued right now?
Zimmer Biomet Holdings (XSWX:ZBH) has a current EV-to-EBITDA of 10.97. The stock's GF Value™ is CHF103.81, compared to a current price of CHF75.00 — trading 27.8% below its estimated fair value. The current EV-to-EBITDA is 10.97, which is 39% below median its 10-year median of 18.07 and 20.8% below the Medical Devices & Instruments industry median of 13.85. Zimmer Biomet Holdings' overall GF Score™ is 76/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Zimmer Biomet Holdings (XSWX:ZBH), the current EV-to-EBITDA is 10.97 as of Jul. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zimmer Biomet Holdings (XSWX:ZBH) Overvalued in 2026?
Based on GuruFocus' analysis, Zimmer Biomet Holdings stock appears to be undervalued.
The current stock price of CHF75.00 is trading 27.8% below its estimated GF Value™ of CHF103.81.
Key valuation signals for XSWX:ZBH:
EV-to-EBITDA: 10.97 (39% below median its 10-year median of 18.07)
GF Value™: CHF103.81 vs. price of CHF75.00 (27.8% below fair value)
Industry Position: 20.8% below the Medical Devices & Instruments median (#181 of 510)
No single metric tells the full story. See the XSWX:ZBH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly two-thirds of total revenue is derived from sales of large joints; another fourth comes from extremities, trauma, sports medicine, and related surgical products. The firm spun out its dental and spine businesses in 2022.
76GF Score
Get the complete analysis for XSWX:ZBH
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:ZBH has been successfully added to your 
